Ventus Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 53 employees on LinkedIn · 10 known investors
Find your way into Ventus Therapeutics
335 people in our graph share verified history with the Ventus Therapeutics team — schools, employers, funds. One of them is your warm intro.
Alan Ezekowitzunlockedknows Michael Crackower · together at Merck (overlapped)
×5knows the team · via Merck
×5knows the team · via Amgen
knows the team · via Versant Ventures
Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.
Founders & leadership
Ventus Therapeutics was founded in 2019 by Judith Lieberman.
JL
Judith LiebermanCo-Founder
DK
Daniel KoerwerinChief Operating OfficerDaniel Koerwer is an executive with experience leading biopharmaceutical companies from early stage through public markets, with background in drug discovery, clinical development, and capital formation for innovative biotechnology firms.
MC
Michael CrackowerinChief Scientific OfficerHe brings over 18 years of pharmaceutical industry experience in drug discovery leadership, with expertise in small-molecule development, respiratory and inflammatory diseases, and a track record of advancing multiple drug candidates into clinical development.
ZM
Zachary McNealyExecutive
MB
Marcelo Bigal, M.D., Ph.D.President and Chief Executive Officer
Board
JR
JD
BB
MB
SJ
Investors · 10
Andreessen HorowitzMenlo Park · $500K – $50M
GV (Google Ventures)Mountain View · $250K – $50M
RA CapitalBoston
SoftBank Vision FundLondon
Versant VenturesSan Francisco · $250K – $5Mvia Markus Warmuth · board
Biotechnology Value FundreportedSan Francisco
Casdin CapitalreportedNew York
Fonds de solidarité FTQreportedMontreal
Qatar Investment AuthorityreportedDoha
Also in the syndicate · 1
Cormorant Asset Management
Reported raises · per SEC filings
Form D private placements$186.8M disclosed across 3 rounds · 2019–2022
▶$70MraisedFeb 2022 · 13 investors · BiotechnologyRule 506(b)
▶$70MraisedFeb 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Daniel KoerwerExecutive Officer
- Josh ResnickDirector
- Markus WarmuthDirector
- Michael CrackowerExecutive Officer
- Jane Pritchett HendersonDirector
- Jerel DavisDirector
- Marcelo BigalExecutive Officer, Director
- Dolca ThomasDirector
- Brendan Bulik-SullivanDirector
- John CassidyDirector
- Zachary McNealyExecutive Officer
- Offering amount
- $140M
- Amount sold
- $70M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$100MraisedApr 2021 · 17 investors · BiotechnologyRule 506(b)
▶$100MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel KoerwerExecutive Officer
- Josh ResnickDirector
- Jerel DavisDirector
- Steven JamesDirector
- Brendan Bulik-SullivanDirector
- Michael CrackowerExecutive Officer
- Zachary McNealyExecutive Officer
- Marcelo BigalExecutive Officer, Director
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$16.8MraisedMay 2020 · 4 investors · BiotechnologyRule 506(b)
▶$16.8MraisedMay 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jerel DavisDirector
- Daniel KoerwerExecutive Officer
- Hao WuDirector
- Zachary McNealyExecutive Officer
- Brendan Bulik-SullivanDirector
- Marcelo BigalExecutive Officer, Director
- Offering amount
- $60.1M
- Amount sold
- $16.8M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Ventus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ventus Therapeutics do?
- Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.
- Who founded Ventus Therapeutics?
- Ventus Therapeutics was founded by Judith Lieberman in 2019.
- Who are Ventus Therapeutics's investors?
- Ventus Therapeutics's investors include Andreessen Horowitz, GV (Google Ventures), RA Capital, SoftBank Vision Fund, Versant Ventures, Biotechnology Value Fund, Casdin Capital, Fonds de solidarité FTQ and 1 more.
- How much funding has Ventus Therapeutics raised?
- Ventus Therapeutics has disclosed $186.8M raised across 3 rounds.
- Where is Ventus Therapeutics headquartered?
- Ventus Therapeutics is headquartered in Waltham, US.